Cadence Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Cadence Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,188	Closed	-$884K	–	590
2018 Q3	$884K	Buy	2,188 +519	+31%	+$198K	0.05%	417
2018 Q2	$576K	Sell	1,669 -897	-35%	-$281K	0.03%	488
2018 Q1	$884K	Buy	2,566 +263	+11%	+$91.5K	0.06%	411
2017 Q4	$866K	Buy	2,303 +6	+0.3%	+$2.43K	0.06%	406
2017 Q3	$1.03M	Buy	+2,297	New	+$1.09M	0.06%	377

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cadence Capital Management's REGN Position: Q4 2018 in Review

Cadence Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 2,188 shares — an estimated $884K sold.

Cadence Capital Management first reported a position in REGN in Q3 2017 and held it in 5 quarters. The position peaked at $1.03M in Q3 2017. 670 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

Cadence Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Cadence Capital Management sold 2,188 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $884K.
Cadence Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 5 quarters.
Cadence Capital Management's Regeneron Pharmaceuticals position peaked at $1.03M in Q3 2017.
670 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Cadence Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.